Literature DB >> 18031260

Biological consequences of statins in Candida species and possible implications for human health.

K Wikhe1, C Westermeyer, I G Macreadie.   

Abstract

The statins, simvastatin and atorvastatin are the most widely prescribed drugs. Statins lower cholesterol levels through their action on HMG-CoA (3-hydroxy-3-methylglutaryl-CoA) reductase, an essential enzyme for the biosynthesis of cholesterol. Fungal HMG-CoA reductases are also inhibited by statins, resulting in reduced levels of ergosterol (the fungal equivalent of cholesterol) and concomitant growth inhibition. This effect occurs in a range of fungal species and possibly affects fungal colonization of people on statin therapy. Furthermore, it may suggest that statins could have a role in new antifungal therapies. Possibly associated with the reduction in ergosterol levels, statins also inhibit respiratory growth. In the yeast, Candida glabrata, passage with statins dramatically increased the frequencies of petite mutants that were devoid of mitochondrial DNA, suggesting that statins caused a defect in the maintenance of mitochondrial DNA. These observations in C. glabrata may provide further insights into side effects of statins in humans undergoing treatment for hypercholesterolaemia. In addition, C. glabrata may be highly useful for the preliminary screening of agents to reduce statin side effects.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18031260     DOI: 10.1042/BST0351529

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  8 in total

1.  Statin therapy and decreased incidence of positive Candida cultures among patients with type 2 diabetes mellitus undergoing gastrointestinal surgery.

Authors:  Elias K Spanakis; Themistoklis K Kourkoumpetis; Grigorios Livanis; Anton Y Peleg; Eleftherios Mylonakis
Journal:  Mayo Clin Proc       Date:  2010-12       Impact factor: 7.616

2.  Suppression of statin effectiveness by copper and zinc in yeast and human cells.

Authors:  Douglas M Fowler; Sara J Cooper; Jason J Stephany; Natalie Hendon; Sven Nelson; Stanley Fields
Journal:  Mol Biosyst       Date:  2010-11-17

3.  Statins in candidemia: clinical outcomes from a matched cohort study.

Authors:  Graeme N Forrest; Angela M Kopack; Eli N Perencevich
Journal:  BMC Infect Dis       Date:  2010-06-04       Impact factor: 3.090

Review 4.  Exploitation of Aspergillus terreus for the Production of Natural Statins.

Authors:  Mishal Subhan; Rani Faryal; Ian Macreadie
Journal:  J Fungi (Basel)       Date:  2016-04-30

Review 5.  Candida glabrata, Friend and Foe.

Authors:  Phyllix Tam; Kirsten Gee; Miryam Piechocinski; Ian Macreadie
Journal:  J Fungi (Basel)       Date:  2015-09-16

6.  Exposure of Aspergillus fumigatus to Atorvastatin Leads to Altered Membrane Permeability and Induction of an Oxidative Stress Response.

Authors:  Ahmad Ajdidi; Gerard Sheehan; Kevin Kavanagh
Journal:  J Fungi (Basel)       Date:  2020-03-26

7.  Antifungal effect of Atorvastatin against Candida species in comparison to Fluconazole and Nystatin.

Authors:  Ava Nasr Esfahani; Zahra Golestannejad; Faezeh Khozeimeh; Parvin Dehghan; Mehrnoosh Maheronnaghsh; Zahra Zarei
Journal:  Med Pharm Rep       Date:  2019-10-25

8.  Simvastatin inhibits planktonic cells and biofilms of Candida and Cryptococcus species.

Authors:  Raimunda Sâmia Nogueira Brilhante; Erica Pacheco de Caetano; Jonathas Sales Oliveira; Débora de Souza Collares Maia Castelo-Branco; Elizabeth Ribeiro Yokobatake Souza; Lucas Pereira de Alencar; Rossana de Aguiar Cordeiro; Tereza de Jesus Pinheiro Gomes Bandeira; José Júlio Costa Sidrim; Marcos Fábio Gadelha Rocha
Journal:  Braz J Infect Dis       Date:  2015-06-26       Impact factor: 3.257

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.